Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
04 Novembro 2024 - 10:00AM
Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical
company developing innovative therapies for patients with rare
cardiopulmonary disease, announced today that it will report its
third quarter 2024 financial results on Monday, November 11, 2024.
The company will host a live webcast at 8:30 a.m. Eastern
Time to discuss its financial results and provide a corporate
update.
The live webcast will be available
on Liquidia's website
at https://liquidia.com/investors/events-and-presentations. A
rebroadcast of the event will be available and archived for a
period of one year at the same location.
About Liquidia CorporationLiquidia
Corporation is a biopharmaceutical company developing
innovative therapies for patients with rare cardiopulmonary
disease. The company’s current focus spans the development and
commercialization of products in pulmonary hypertension and other
applications of its proprietary PRINT® Technology. PRINT
enabled the creation of Liquidia’s lead candidate, YUTREPIA™
(treprostinil) inhalation powder, an investigational drug for the
treatment of pulmonary arterial hypertension (PAH) and pulmonary
hypertension associated with interstitial lung disease (PH-ILD).
The company is also developing L606, an investigational
sustained-release formulation of treprostinil administered
twice-daily with a next-generation nebulizer, and currently markets
generic Treprostinil Injection for the treatment of PAH. To learn
more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:Jason AdairChief Business
Officer919.328.4350jason.adair@liquidia.com
Media: Patrick WallaceDirector, Corporate
Communications919.328.4383patrick.wallace@liquidia.com
Liquidia (NASDAQ:LQDA)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Liquidia (NASDAQ:LQDA)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024